Fetal vs Perinatal EVs as potential OA Therapeutics

September 2nd, 2025, Vienna, Austria

We are pleased to share a new publication led by scientists from VETERM Research Group Veterinary Medicine University Vienna, featuring the use of our Wharton’s Jelly-derived (WJ-MSC/TERT273) and placenta-derived MSCs (P-MSC/TERT308). EVs derived from these two telomerized perinatal cells were compared to ovine fetal articular chondrocytes and ovine fetal umbilical cord blood MSCs on inflamed ovine adult chondrocytes and synoviocytes in vitro, as potential therapeutic treatment for osteoarthritis.

Tarasova, K., Arteaga, M., Kidtiwong, A. et al. Ontogenetic stage and type of donor cells shape extracellular vesicles’ therapeutic potential for osteoarthritis. Stem Cell Res Ther 16, 478 (2025). https://doi.org/10.1186/s13287-025-04585-y